Embecta Corp(EMBC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:01 PM ET (Korea 11/7 06:01)
Full metrics table
| Index | RUT | P/E | 4.17 | EPS (ttm) | 1.48 | Insider Own | 8.24% | Shs Outstand | 56.7M | Perf Week | -0.96% |
| Market Cap | 0.35B | Forward P/E | 3.51 | EPS next Y | -3.96% | Insider Trans | 2.38% | Shs Float | 52.0M | Perf Month | 7.65% |
| Enterprise Value | 1.63B | PEG | - | EPS next Q | 0.29 | Inst Own | 86.1% | Short Float | 11.29% | Perf Quarter | 24.05% |
| Income | 0.09B | P/S | 0.34 | EPS this Y | -37.76% | Inst Trans | -18.52% | Short Ratio | 4.66 | Perf Half Y | 70.05% |
| Sales | 1.02B | P/B | - | EPS next 5Y | -12.88% | ROA | 7.22% | Short Interest | 5.87M | Perf YTD | -47.9% |
| Book/sh | -10.81 | P/C | 1.61 | EPS past 3/5Y | -25.52% - | ROE | - | 52W High | -58.48% ($14.91) | Perf Year | -54.01% |
| Cash/sh | 3.85 | P/FCF | 2.13 | Sales past 3/5Y | -1.47% -0.1% | ROIC | 11.83% | 52W Low | 123.47% ($2.77) | Perf 3Y | -60.52% |
| Dividend Est. | $0.25 (4.07%) | EV/EBITDA | 5.05 | EPS Y/Y TTM | 4.11% | Gross Margin | 59.63% | Volatility(W/M) | 6.92% 5.12% | Perf 5Y | - |
| Dividend TTM | 0.32 | EV/Sales | 1.6 | Sales Y/Y TTM | -7.6% | Oper. Margin | 26.38% | ATR (14) | 0.34 | Perf 10Y | - |
| Dividend Ex-Date | 2026/8/27 | Quick Ratio | 1.17 | EPS Q/Q | -53.64% | Profit Margin | 8.59% | RSI (14) | 49.97 | Recom | 3.2 |
| Dividend Gr. 3/5Y | 58.74% - | Current Ratio | 1.68 | Sales Q/Q | -8.05% | SMA20 | -3.21% ($6.4) | Beta | 0.79 | Target Price | $4 |
| Payout | 37.05% | Debt/Eq | - | Earnings | 2026/8/7 | SMA50 | 5.66% ($5.86) | Rel Volume | 0.49 | Prev Close | $6.33 |
| Employees | 1850 | LT Debt/Eq | - | EPS/Sales Surpr. | 110.68% 6.75% | SMA200 | -1.5% ($6.28) | Avg Volume(3M) | 1.26M | Price | $6.19 |
| IPO | 2022/3/22 | Option/Short | Yes/Yes | Trades | 6215 | Volume | 623,167 | Change | -2.21% |
💉 Embecta (EMBC) is a global medical device company specializing in insulin delivery solutions for diabetes patients. Its core product, pen needles, are disposable sterile needles that attach to insulin pen injectors, generating a stable stream of recurring revenue due to their nature as consumables requiring repeated purchases. The company supplies its products to numerous countries through its global distribution network.
Over the past 1 year, roughly in the middle
58% below its 1-year high.
Traded less than usual. That is 49% of its average volume.
EMBC makes money exceptionally well
Of every $100 in sales, $26.38 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -37.8% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $505. Peers typically go for $1,500. Compared with its own 5-year average, it is 60% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is negative
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -60.5%.
Tap to view numbers
Dividends are paid consistently
Pays 4.07% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 86.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #32 of 51 in the industry
Based on market cap of $351M.
FAQ
What kind of company is EMBC?
EMBC belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of EMBC?
The market cap of EMBC is approximately $351M, ranking 3,457 within its sector.
Does EMBC pay dividends?
EMBC has a dividend yield of approximately 4.07%, with an annual dividend of $0.25.
What is the P/E ratio of EMBC?
EMBC has a P/E ratio of approximately 4.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for EMBC?
EMBC has recorded a 52-week high of $14.91 and a low of $2.77.
